Parameter | Overall (n = 96) | mCRPC (n = 71) | mCSPC (n = 25) | P* |
---|---|---|---|---|
Age at initial prostate cancer diagnosis (y) | 66.2 (59.7, 71.6) | 67.4 (59.7, 72.9) | 64.2 (59.7, 65.9) | 0.012 |
Gleason grade group at initial diagnosis | 0.439 | |||
1 | 5 (5.2) | 4 (5.6) | 1 (4.0) | |
2 | 7 (7.3) | 7 (9.9) | 0 | |
3 | 19 (19.8) | 12 (16.9) | 7 (28.0) | |
4 | 22 (22.9) | 16 (22.5) | 6 (24.0) | |
5 | 36 (37.5) | 27 (38.0) | 9 (36.0) | |
Not available | 7 (7.3) | 5 (7.0) | 2 (8.0) | |
Initial prostate cancer treatment | 0.022 | |||
Prostatectomy ± hormonal therapy | 40 (41.7) | 24 (33.8) | 16 (64.0) | |
Radiation ± hormonal therapy | 27 (28.1) | 24 (33.8) | 3 (12.0) | |
Hormonal therapy | 29 (30.2) | 23 (32.4) | 6 (24.0) | |
Initial cancer diagnosis to castration resistance (mo) | — | 50.5 (13.9, 125.3) | — | — |
Initial cancer diagnosis to treatment† start (mo) | 42.5 (11.9, 116.0) | 57.9 (15.4–127.1) | 8.4 (6.2–74.5) | 0.002 |
Castration resistance to treatment† start (mo) | — | 1.2 (0.3, 5.5) | — | — |
Age at start of treatment† (y) | 71.0 (65.8, 79.6) | 73.8 (67.1, 82.1) | 67.9 (63.7, 70.7) | 0.002 |
Treatment type | 0.161 | |||
Abiraterone plus prednisone | 57 (59.4) | 39 (54.9) | 18 (72.0) | |
Enzalutamide | 39 (40.6) | 32 (45.1) | 7 (28.0) | |
Laboratory parameters at treatment† start | ||||
Prostate-specific antigen (ng/mL) | 13.3 (3.1, 32.4) | 15.1 (4.4, 37.7) | 3.5 (1.0, 23.4) | 0.016 |
Albumin (g/dL) | 4.2 (4.1, 4.4) | 4.2 (4.0, 4.4) | 4.4 (4.1, 4.7) | 0.019 |
Alkaline phosphatase (U/L) | 88 (70, 141) | 94 (70, 150) | 75.5 (62, 96.5) | 0.079 |
Hemoglobin (g/dL) | 12.7 (11.8, 13.6) | 12.3 (11.3, 13.1) | 13.8 (12.6, 14.8) | <0.001 |
Lactate dehydrogenase (U/L) | 201 (173, 251) | 218 (182, 260) | 187 (155, 204) | 0.003 |
18F-FDG PET/CT data | ||||
Time from PET/CT to treatment† start (d) | 22.5 (11.5, 40) | 22 (12, 36) | 23 (8, 43) | 0.708 |
Injected 18F-FDG activity (MBq) | 459 (437, 459) | 463 (433, 488) | 451 (440, 463) | 0.269 |
Time from tracer injection to scan start (min) | 67 (61, 79.5) | 70 (63, 80) | 62 (60, 73) | 0.052 |
SUVmax (g/mL) | 7.1 (5.3, 10.9) | 7.2 (5.5, 11.7) | 5.9 (4.8, 9.0) | 0.188 |
Number of 18F-FDG–avid metastases | 4 (2, 14) | 5 (3, 15) | 2 (0, 8) | 0.018 |
Whole-body metabolic tumor volume (mL) | 45.7 (13.0, 120.8) | 57.0 (20.9, 145.3) | 15.5 (0, 62.9) | 0.005 |
Whole-body TLG (g) | 123.3 (38.5, 568.1) | 167.0 (48.7, 583.7) | 59.5 (0, 194.1) | 0.004 |
Follow-up after treatment† start in survivors (mo) | 56.3 (37.7, 66.8) | 45.3 (32.9, 65.7) | 60.1 (29.7, 67.8) | 0.334 |
Median survival after treatment† start (mo) [95% CI] | 39.7 [28.6, 53.5] | 27.8 [22.1, 39.7] | 76.1 [50.3, -] | <0.001 |
* For comparison of mCRPC and mCSPC patients.
† Treatment with abiraterone plus prednisone, or enzalutamide.
Qualitative data are absolute counts and percentage; continuous data are median and interquartile range.